Molecular characterization of novel melanoma cell lines

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 239-247

  Zanna, P ^a   Maida, I ^a   Turpin Sevilla, M C ^b   Susca, F C ^a   Filotico, R ^c   Arciuli, M ^a   Cassano, N ^a   Vena, G A ^a   Cicero, R ^a   Guida, Gabriella ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF MURCIA   (Spain)

^c A Perrino Hospital   (Italy)

Author keywords

BRAF; Chromosomal alterations; Cutaneous melanoma; Human melanoma cell lines; Karyotype; Melanogenesis; Tyrosinase

Indexed keywords

B RAF KINASE; MELANOCORTIN 1 RECEPTOR; MONOPHENOL MONOOXYGENASE; TYROSINE 3 MONOOXYGENASE; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN;

AGED; ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HETEROPLOIDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; MALE; MELANOMA CELL; ONCOGENE N RAS; PIGMENTATION; AMELANOTIC MELANOMA; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; KARYOTYPING; MELANOMA; METABOLISM; PATHOLOGY; POLYPLOIDY; PROGNOSIS; SKIN TUMOR; TUMOR CELL LINE;

BIOLOGICAL MARKERS; CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; CYTOGENETIC ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HUMANS; KARYOTYPING; MELANOMA; MELANOMA, AMELANOTIC; MONOPHENOL MONOOXYGENASE; PIGMENTATION; POLYPLOIDY; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 80052870931     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146:1-6.
2. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet 2009; 126:499-10.
3. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6:313-9. (Pubitemid 39361432)
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54. (Pubitemid 34716871)
5. James MR, Dumeni T, Stark MS, Duffy DL, Montgomery GW, Martin NG, Hayward NK. Rapid screening of 4000 individuals for germ-line variations in the BRAF gene. Clin Chem 2006; 52:1675-8. (Pubitemid 44330700)
6. Schmitz S, Thomas PD, Allen TM, Poznansky MJ, Jimbow K. Dual role of melanins and melanin precursors as photoprotective and phototoxic agents: inhibition of ultraviolet radiation-induced lipid peroxidation. Photochem Photobiol 1995; 61:650-5.
7. Ito S. High-performance liquid chromatography (HPLC) analysis of eu- and pheomelanin in melanogenesis control. J Invest Dermatol 1993; 100:166-71.
8. Abdel-Malek Z, Scott MC, Suzuki I, Tada A, Im S, Lamoreux L, Ito S, Barsh G, Hearing VJ. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Res 2000; 13:156-62.
9. Sturm RA, Teasdale RD, Box NF. Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 2001; 277:49-62. (Pubitemid 32972108)
10. Carless MA, Griffiths LR. Cytogenetics of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624:227-40.
11. Höglund M, Gisselsson D, Hansen GB, White VA, Säll T, Mitelman F, Horsman D. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108:57-65. (Pubitemid 37444444)
12. Jimenez-Cervantes C, Olivares C, Gonzalez P, Morandini R, Ghanem G, Garcia-Borron JC. The Pro162 variant is a loss-of-function mutation of the human melanocortin 1 receptor gene. Invest Dermatol 2001; 117:156-8. (Pubitemid 32652455)
13. Jara JR, Solano F, Lozano JA. Assays for mammalian tyrosinase: a comparative study. Pigment Cell Res 1988; 1:332-9.
14. Sánchez Más J, Olivares Sánchez C, Ghanem G, Haycock J, Lozano Teruel JA, García-Borrón JC, Jiménez-Cervantes C. Loss-of-function variants of the human melanocortin-1 receptor gene in melanoma cells define structural determinants of receptor function. Eur J Biochem 2002; 269:6133-41. (Pubitemid 35461826)
15. Sánchez-Laorden BL, Sánchez-Más J, Martínez-Alonso E, Martínez-Menárguez JA, García-Borrón JC, Jiménez-Cervantes C. Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects. J Invest Dermatol 2006; 126:172-81. (Pubitemid 43336110)
16. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer 1998; 41:248-55.
17. Höglund M, Frigyesi A, Sall T, Gisselsson D, Mitelman F. Statistical behavior of complex cancer karyotypes. Genes Chromosomes Cancer 2005; 42:327-41. (Pubitemid 40271277)
18. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 1995; 83:93-104.
19. Namiki T, Yanagawa S, Izumo T, Ishikawa M, Tachibana M, Kawakami Y, Yokozeki H, Nishioka K, Kaneko Y. Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet 2007; 157:1-11. (Pubitemid 40164851)
20. Matsuta M, Imamura Y, Matsuta M, Sasaki K, Kon S. Detection of numerical chromosomal aberrations in malignant melanomas using fluorescence in situ hybridization. J Cutan Pathol 1997; 24:201-5. (Pubitemid 27187014)
21. Gagos S, Papaioannou G, Chiourea M, et al. Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity. Mol Cytogenet 2008; 1:20.
22. Bastian BC, LeBoit PE, Hamm H, Bröcker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58:2170-5. (Pubitemid 28232904)
23. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9:6483-8. (Pubitemid 38031837)
24. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett 2004; 214:133-47. (Pubitemid 39213938)
25. Rother J, Jones D. Molecular markers of tumor progression in melanoma. Curr Genomics 2009; 10:231-9.
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-7. (Pubitemid 36373628)
27. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934. (Pubitemid 34976022)
28. Singer G, Oldt R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95:484-6. (Pubitemid 36432423)
29. Wang N, Hebert DN. Tyrosinase maturation through the mammalian secretory pathway: bringing color to life. Pigment Cell Res 2006; 19:3-18.